A459 questions looked into the skin condition, and one question described the localization of possible lesions on the skin. Moreover, a psychometric validation has enable to confirm the internal consistency and very good reproducibility of the questionnaire CONCLUSIONS: The ongoing validation study carried in several dermatology hospital units will allow to determine 3 levels of presumed diagnosis of Atopic Dermatitis: «unlikely», «likely» or «possible»; which will help the caregiver decide whether the patient should be referred to a dermatologist to get appropriate treatment. OBJECTIVES: To develop a brief self-administered questionnaire able to measure patient satisfaction with treatments of skin diseases of the hands, with good psychometric properties. METHODS: An initial version of the questionnaire composed by 38 items, organized in 6 dimensions, was proposed. Items were extracted from 3 patient's focus-groups and ratified by a 7 expert panel and were presented to a pilot sample to test comprehension. This full version was administered to a sample of 217 patients with skin diseases of the hands recruited at 18 representative hospitals in Spain. In order to assess convergent validity Morisky-Green compliance scale, SF-12 HRQoL questionnaire and a health status VAS were also used. Treatment effectiveness and tolerability were also measured. Exploratory factor analysis was used for item reduction and confirmatory factor analysis for dimensionality assessment. Internal consistency and split-half methods were used for reliability. Item discrimination and kwon group's validity (gender, age, severity, and treatment) were also assessed.
1
Galen Research Ltd, Manchester, UK, 2 The University of Manchester, Manchester, UK OBJECTIVES: Skin scars impact quality of life (QoL), quantification of which is essential to evaluate the effectiveness of treatment. As no suitable instruments were available the objective of the study was to develop and validate the first patient-reported scale of scar-specific symptoms and QoL. METHODS: Questionnaire content was derived from qualitative interviews with UK scar patients. Face and content validity were assessed by cognitive debriefing interviews conducted with patients. The final instrument was determined using Rasch analysis and psychometrically assessed in a validation survey. RESULTS: Five hundred and sixty-seven potential items were extracted from 34 qualitative interview transcripts. Following review and reduction, 16 symptom and 36 QoL items were identified. The draft scales were found to be relevant, clear and easy to use in 16 patient interviews. Two QoL items were deleted as patients considered them too extreme. Following the validation survey (n 103), 10 QoL and 3 symptom items were removed: eight misfit the Rasch model (Chi 2 p 0.05); four were redundant and one functioned differently according to age. Rasch analysis confirmed two unidimensional scales (p 0.05). Internal consistency was good Internal consistency was good for both the symptoms and QoL scales (0.84 and 0.85) as was test-retest reliability (0.83 and 0.89 respectively). The symptom scale was shown to be statistically signifi-
The symptom scale was shown to be statistically significantly related (as expected) to scores on the Hospital Anxiety and Depression Scale (HADS) and the clinician-completed Manchester Scar Score (MSS). The QoL scale was also statistically significantly related to scores on these measures and on patientreported scar severity. CONCLUSIONS: PRISM is the first scientifically rigorous patient-reported instrument designed specifically for scar patients. It consists of two unidimensional scales with good psychometric and scaling properties: QoL (24 items) and symptoms (13 items). PRISM is well accepted by patients, easy to use and should prove valuable for assessing scar disease severity in clinical trials and practice.
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QUALITY OF LIFE IN CHRONIC HAND ECZEMA AS MEASURED BY THE DERMATOLOGY LIFE QUALITY INDEX
Freemantle N 1 , Aldridge R 2 , Stanley G 3 1 University of Birmingham, Birmingham, West Midlands, UK, 2 University of Edinburgh, Edinburgh, Edinburgh, UK, 3 Basilea Medical, Guildford, Surrey, UK OBJECTIVES: The Quality of Life (QoL) impact of chronic hand eczema (CHE) is expected to be significant because of the high functional, social and psychological impact of this disease but has rarely been assessed with validated tools. This study determined the effect of CHE severity on patient QoL by the Dermatology Life Quality Index (DLQI). METHODS: Data from a Phase II study of oral alitretinoin for the treatment of moderate to severe CHE unresponsive to potent topical corticosteroids was used to measure changes in QoL according to Physician's Global Assessment (PGA) of disease severity. 162 matched DLQI and PGA observations were analysed using mixed models. The PGA is a global 5-point rating of CHE severity based on multiple signs and symptoms. The DLQI is a simple questionnaire validated in several skin diseases and different languages. Ten questions scored 0-3 are summed, with a total score of 0 (best QoL) to 30 (worst QoL). DLQI 5 is considered clinically significant and DLQI 11-20 is considered to indicate a very large impact of skin disease on QoL. RESULTS: Increasing severity of CHE was associated with a conditional mean DLQI score as follows: 'clear/almost clear' 1.74, 'mild' 5.93, 'moderate' 9.78, and 'severe' 15.08. Changes in DLQI score from PGA 'severe' to milder states during the 12 week study were as follows: 'moderate' ( 5.30), 'mild' ( 9.15), 'almost clear' ( 12.03), and 'clear' ( 14.56). All changes were statistically significant (p 0.0001) and exceeded the Minimal Important Difference (MID) for CHE estimated to be 2.53 in a recent German observational study. CONCLUSIONS: The QoL of patients with CHE is significantly influenced by clinical disease severity as measured by the PGA instrument. Treatment which reduces clinical severity of CHE is likely to be worthwhile from the patient perspective in view of the significant improvement in QoL that may result. ) was an open-label, multicenter, Phase IIIb study in Canada. Patients with active moderate to severe plaque psoriasis who failed to respond to, or were intolerant of, standard prior therapies received adalimumab (80 mg) at Week 0 followed by adalimumab (40 mg) every other week. Changes in mg) at Week 0 followed by adalimumab (40 mg) every other week. Changes in the outcomes including the Psoriasis Area and Severity Index (PASI), Beck Depression Inventory-II (BDI) and EQ-5D VAS at baseline, weeks 16 and 24 were evaluated. A multivariate mixed-effect regression was fitted to identify the independent contribution of skin severity (PASI) and depression (BDI) on HRQoL (EQ-5D VAS). RESULTS: A total of 203 patients (61% male, mean age:46, mean PASI:20) were enrolled at 26 sites. Statistically significant improvements in PASI, EQ-5D VAS and BDI were seen at week 16 (improvements of 16.0, 10.1, 4.2, respectively all p 0.001) and 24 (improvements of 16.1, 10.7, 4.3, respectively all p 0.001). The model found that both PASI ( 0.40, p 0.004) and BDI ( 0.54, p 0.002) were independent predictors of EQ-5D VAS. The interaction between BDI and females was also significant ( 0.64, p 0.006). CONCLUSIONS: HRQoL in patients with plaque psoriasis is influenced independently by both skin severity and depression. While the etiology of depression is likely through skin severity, it appears likely that both contribute to the improvements in HRQoL seen with adalimumab treatment.
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